Skip to main content
ADMA BIOLOGICS, INC. logo

ADMA BIOLOGICS, INC. — Investor Relations & Filings

Ticker · ADMA ISIN · US0008991046 US Manufacturing
Open in API
Filings indexed 962 across all filing types
Latest filing 2023-11-08 Earnings Release
Country US United States of America
Listing US ADMA

About ADMA BIOLOGICS, INC.

https://www.admabiologics.com/

ADMA Biologics, Inc. is an end-to-end commercial biopharmaceutical company that develops, manufactures, and commercializes specialty plasma-derived biologics. The company's portfolio features FDA-approved immune globulin (Ig) products for the treatment of immune-compromised patients and individuals at risk for certain infections. ADMA Biologics operates a vertically integrated manufacturing process for its specialty biologic products and utilizes a patented immunotechnology platform, which includes a proprietary microneutralization assay to measure neutralizing antibody levels in plasma. The company also offers contract manufacturing capabilities.

Recent filings

Filing Released Lang Actions
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated November 8, 2023, reporting the issuance of a press release announcing financial results for the quarter ended September 30, 2023. The text explicitly states that the press release is furnished as an exhibit and that the information is not deemed filed for certain regulatory purposes. The document length is 3436 characters, which is relatively short and primarily serves as an announcement of the earnings release rather than containing the financial results themselves. According to the 'Menu vs Meal' rule, this is an announcement of a report (the earnings release) rather than the report itself. Therefore, the appropriate classification is Earnings Release (ER).
2023-11-08 English
Director's Dealing 2023
Director's Dealing
2023-10-04 English
Director's Dealing 2023
Director's Dealing
2023-10-04 English
Director's Dealing 2023
Director's Dealing
2023-10-02 English
8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is used for current reports to announce major events that shareholders should know about. The key content is the appointment of a new director to the Board of Directors, including biographical details and compensation information. This fits the description of announcements related to changes in the company's board or senior management. The document is not a full annual report, earnings release, or other financial report, but specifically an announcement of a board appointment. Therefore, the appropriate classification is Board/Management Information (MANG). The document length and content confirm it is not a brief announcement or a certification, but a substantive filing about management changes.
2023-10-02 English
Director's Dealing 2023
Director's Dealing
2023-08-30 English

Browse filings by year

21 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.